Apimeds Pharmaceuticals US (APUS) Return on Assets (2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Return on Assets came in at 0.0% in Q4 2025, up 73.59% on a QoQ basis from 0.01% in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Return on Assets (2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 1 years of Return on Assets data on file, last reported at 0.0% in Q4 2025.

Quarterly Return on Assets changed N/A year-over-year to 0.0% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0% (changed N/A YoY) and the FY2025 annual result came in at 0.0%, up 11.0% from the prior year.
Return on Assets climbed to 0.0% in Q4 2025, from 0.01% in the prior quarter.
In the past five years, Return on Assets ranged from a high of 0.0% in Q4 2025 to a low of 0.11% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	0.00%
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	0.00%
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	0.00%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	0.00%
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	0.00%
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	0.00%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	0.00%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	0.00%
10	Apimeds Pharmaceuticals US	7.20 Mn	7.20 Mn	-	0.00%

Download Data